2,925 research outputs found
VR for cultural heritage valorization: a communication problem
No full textVirtual Reality is presented in several ways, following the specific point of view considered. For example, in many works Virtual Reality is considered for the effects on human users, in other for its application, such as medicine and education. Other studies present Virtual Reality as a method to explore physical phenomena. In this work, after presenting a taxonomy of Virtual Representations and some examples of current applications, the concept of Virtual Reality is introduced as a communication process, specifically in the context of Cultural Heritage applications, with particular focus on pragmatic and emotional user involvement
Deferasirox (Exjade®) for the treatment of iron overload
No full textDeferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis. Copyright © 2009 S. Karger AG, Basel.Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056-NEJM199807023390102; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Bennett JM, 2008, AM J HEMATOL, V83, P858, DOI 10.1002-ajh.21269; Beutler E, 2007, BLOOD CELL MOL DIS, V39, P140, DOI 10.1016-j.bcmd.2007.03.009; Cappellini M. D., 2008, BLOOD, V112, P3875; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; Cappellini MD, 2008, HAEMATOL-HEMATOL J, V93, P336; CAPPELLINI MD, 2008, BLOOD, V112, P3878; Cappellini MD, 2007, BLOOD, V110, p816A; Cappellini MD, 2008, BLOOD, V112, P5411; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136-bmj.327.7424.1151; Cohen AR, 2008, BLOOD, V111, P583, DOI 10.1182-blood-2007-08-109306; COSSU P, 1981, EUR J PEDIATR, V137, P267, DOI 10.1007-BF00443255; Daar S, 2009, EUR J HAEMATOL, V82, P454, DOI 10.1111-j.1600-0609.2008.01204.x; Damanhouri G, 2008, BLOOD, V112, P5409; *DIAM BLACKF AN SU, DIAM BLACKF AN SYNDR; Esposito BP, 2003, BLOOD, V102, P2670, DOI 10.1182-blood-2003-03-0807; Galanello R, 2003, J CLIN PHARMACOL, V43, P565, DOI 10.1177-0091270003253350; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1343; Garbowski M, 2008, BLOOD, V112, P116; Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P1; Gattermann N, 2008, BLOOD, V112, P633; Goubran HA, 2007, BLOOD, V110, p676A; GREENBERG PL, 2008, BLOOD, V112, P5083; Hellstrom-Lindberg E, 2005, SEMIN HEMATOL, V42, pS10, DOI 10.1053-j.seminhematol.2005.01.002; Ibrahim AS, 2007, J CLIN INVEST, V117, P2649, DOI 10.1172-JCI32338; International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA, V256, P1749; Jastaniah W, 2008, PEDIATR BLOOD CANCER, V50, P319, DOI 10.1002-pbe.21260; Kostler E, 2005, EXPERT OPIN PHARMACO, V6, P377, DOI 10.1517-14656566.6.3.377; LEE JW, 2008, BLOOD, V112, P439; LIST AF, 2008, BLOOD, V112, P634; Marsh JCW, 2003, BRIT J HAEMATOL, V123, P782, DOI 10.1046-j.1365-2141.2003.04721.x; MIN YH, 2008, BLOOD, V112, P3649; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Nisbet-Brown E, 2003, LANCET, V361, P1597, DOI 10.1016-S0140-6736(03)13309-0; *NOV PHARM CORP, EXJ DEF PRESCR INF N; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; Olivieri NF, 1997, BLOOD, V89, P739; OLIVIERI NF, 1992, BLOOD, V79, P2741; Origa R, 2008, HAEMATOL-HEMATOL J, V93, P1095, DOI 10.3324-haematol.12484; PENNELL D, 2008, BLOOD, V112, P3874; Pennell DJ, 2008, BLOOD, V112, P3873; Pietrangelo A, 2007, BLOOD, V110, p788A; PIETRANGELO A, 2009, J HEPATOL UNPUB; Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873; Piga A, 2008, BLOOD, V112, P3883; PIGA A, 2008, BLOOD, V112, P5413; PORTER JB, 2008, BLOOD, V112, P1048; PORTER JB, 2008, BLOOD, V112, P1419; Porter JB, 2008, BLOOD, V112, P3881; Porterfield D, 2005, WEED TECHNOL, V19, P1, DOI 10.1614-WT-02-006; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111-j.1600-0609.2007.00985.x; Taher A, 2009, EUR J HAEMATOL, V82, P458, DOI 10.1111-j.1600-0609.2009.01228.x; Taher A, 2006, BLOOD CELL MOL DIS, V37, P12, DOI 10.1016-j.bcmd.2006.04.005; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2005, AM J HEMATOL, V80, P70, DOI 10.1002-ajh.20402; VICHINSKY E, 2008, BLOOD, V112, P1420; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Wood JC, 2008, BLOOD, V112, P3882; Wood JC, 2006, TRANSL RES, V148, P272, DOI 10.1016-j.trsl.2006.05.005; ZURLO MG, 1989, LANCET, V2, P2726222
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
No full textBackground: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant morbidity and mortality. While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h- day, 5-7 days-week. This regimen is problematic and impacts significantly on patients' daily life. Objective: To evaluate the efficacy and tolerability of deferasirox, a once-daily oral iron chelator. Method: To review the available data reported in peer-reviewed journals (using PubMed) and at medical conferences. Results-conclusions: Deferasirox is effective in reducing or maintaining iron burden in patients with transfusion-dependent anaemias. As deferasirox is orally administered, the inconvenience of parenteral administration with deferasirox is avoided. Deferasirox improves patient satisfaction and is expected to improve compliance with iron chelation therapy. © 2008 Informa UK Ltd.Abdelrazik N, 2007, HEMATOLOGY, V12, P577, DOI 10.1080-10245330701521614; Aydinok Y, 1999, ACTA HAEMATOL-BASEL, V102, P17, DOI 10.1159-000040962; Borgna-Pignatti C, 1998, ANN NY ACAD SCI, V850, P227, DOI 10.1111-j.1749-6632.1998.tb10479.x; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056-NEJM199409013310902; Cappellini MD, 2007, CLIN THER, V29, P909, DOI 10.1016-j.clinthera.2007.05.007; CAPPELLINI MD, 2007, BLOOD, V110; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182-blood-2005-08-3430; Ceci A, 2002, BRIT J HAEMATOL, V118, P330, DOI 10.1046-j.1365-2141.2002.03554.x; COHEN AR, 2006, HEMATOLOGY AM SOC HE, V42; Cohen AR, 2003, BLOOD, V102, P1583, DOI 10.1182-blood-2002-10-3280; Cunningham MJ, 2004, BLOOD, V104, P34, DOI 10.1182-blood-2003-09-3167; DAAR S, 2006, BLOOD, V108; Delea TE, 2007, TRANSFUSION, V47, P1919, DOI 10.1111-j.1537-2995.2007.01416.x; ELEFTHERIOU P, 2006, HAEMATOLOGICA S1, V91; Gabutti V, 1996, ACTA HAEMATOL-BASEL, V95, P26; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1241; Galanello R, 2003, J CLIN PHARMACOL, V43, P565, DOI 10.1177-0091270003253350; Galanello R, 2006, HAEMATOL-HEMATOL J, V91, P1343; Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P18; Gattermann N, 2007, LEUKEMIA RES, V31, pS109, DOI 10.1016-S0145-2126(07)70199-6; Glickstein H, 2006, BLOOD, V108, P3195, DOI 10.1182-blood-2006-05-020867; Karnon J, 2008, CURR MED RES OPIN, V24, P1609, DOI 10.1185-03007990802077442; Leitch HA, 2007, LEUKEMIA RES, V31, pS7, DOI 10.1016-S0145-2126(07)70460-5; MAHINDRA A, 2007, BLOOD, V110; Nick H, 2003, CURR MED CHEM, V10, P1065, DOI 10.2174-0929867033457610; Nick H, 2007, SEMIN HEMATOL, V44, pS12, DOI 10.1053-j.seminhematol.2007.03.005; Nick H, 2002, ADV EXP MED BIOL, V509, P185; Nisbet-Brown E, 2003, LANCET, V361, P1597, DOI 10.1016-S0140-6736(03)13309-0; *NOV PHARM AG, 2006, EXJ DEF SUMM PROD CH; *NOV PHARM AG, 2006, EXJ BAS PRESCR INF; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056-NEJM199907083410207; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; Olivieri NF, 1997, BLOOD, V89, P739; Otto-Duessel M, 2007, EXP HEMATOL, V35, P1069, DOI 10.1016-j.exphem.2007.04.001; PIETRANGELO A, 2007, BLOOD, V110; Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873; PLATZBECKER U, 2007, IMPACT TRANSFUSION D, V110; Porter JB, 2005, BLOOD, V106; PORTER JB, 2007, BLOOD, V110; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111-j.1600-0609.2007.00985.x; Rose C, 2007, BLOOD, V110; ROSE C, 2006, HAEMATOLOGICA S1, V91; TAHER A, 2007, HAEMATOLOGICA S1, V92; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111-j.1365-2141.2006.06455.x; Vichinsky E, 2008, ACTA HAEMATOL-BASEL, V119, P133, DOI 10.1159-000125550; Vichinsky E, 2008, AM J HEMATOL, V83, P398, DOI 10.1002-ajh.21119; Wood J, 2007, BLOOD, V110; Wood JC, 2006, TRANSL RES, V148, P272, DOI 10.1016-j.trsl.2006.05.005; 1999, FERRIPROX SUMMARY PR18171
Guidelines for the Clinical Management of Thalassaemia [Internet]
No full textWritten by some of the world’s leading authorities on haemoglobin disorders, this second revised edition of Guidelines for the Clinical Management of Thalassaemia provides medical professionals with a clear, comprehensive guide to the optimal treatment of thalassaemia, based on scientific evidence, clinical studies and observations. The information provided here has been meticulously compiled by experts fully aware of the many different circumstances in which medical personnel strive to treat patients with thalassaemia. As such, it sets out to provide a full guide to the treatment to which every patient everywhere is entitled, including access to sufficient quantities of safe blood and iron chelation therapy, as well as offering a comprehensive assessment of groundbreaking advances in chelation therapy, other treatment options and the long-awaited final cure, including stem cell transplantation and gene therapy
Beta-thalassemia intermedia: An overview
No full text[No abstract available]Aessopos A, 2005, CHEST, V127, P1523, DOI 10.1378-chest.127.5.1523; Aessopos A, 2001, BLOOD, V97, P3411, DOI 10.1182-blood.V97.11.3411; CAPELLINI MD, 2002, HEMATOL J, V65; CAPELLINI MD, 2007, GUIDELINES CLIN MANA, pCH11; Cappellini MD, 2005, SEMIN HEMATOL, V42, pS19, DOI 10.1053-j.seminhematol.2005.01.001; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; Castelli R, 2004, AM J MED SCI, V328, P299, DOI 10.1097-00000441-200411000-00012; Chehal Aref, 2003, Spine (Phila Pa 1976), V28, pE245, DOI 10.1097-00007632-200307010-00024; Dixit A, 2005, ANN HEMATOL, V84, P441, DOI 10.1007-s00277-005-1026-4; Eldor A, 2002, BLOOD, V99, P36, DOI 10.1182-blood.V99.1.36; GIMMON Z, 1982, PLAST RECONSTR SURG, V69, P320, DOI 10.1097-00006534-198202000-00023; Karimi M, 2005, J PEDIAT HEMATOL ONC, V27, P380, DOI 10.1097-01.mph.0000174386.13109.28; Kushner J P, 2001, Hematology Am Soc Hematol Educ Program, P47; Mourad FH, 2003, BRIT J HAEMATOL, V121, P187, DOI 10.1046-j.1365-2141.2003.04240.x; Origa R, 2005, ANN NY ACAD SCI, V1054, P451, DOI 10.1196-annals.1345.051; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056-NEJM199301143280202; St Pierre TG, 2005, BLOOD, V105, P855, DOI 10.1182-blood-2004-01-0177; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; TAHER A, 2006, BLOOD CELL MOL DIS, V27, P12; TAHER A, 2007, ASH ANN M, V110, P3818; Weatherall DJ, 2001, J HEMATOL S1, V86, P18694
Determinazione mediante GC-MS e HPLC dei principi attivi di amfetamine allucinogene in compresse e capsule tipo 'Ecstasy' provenienti dal mercato clandestino: rilievi statistici su sei anni di attività del laboratorio di Tossicologia Forense
No full textUnveiling the creative self in midlife: A qualitative study of Italian women’s psychosocial transformation journeys
No full text: This qualitative study explores the psychosocial experiences of midlife Italian women, focusing on the evolution of their creative self. Using Interpretative Phenomenological Analysis, we examined narratives from eight women aged 51-62, capturing their spontaneous perception of the changes characterizing this phase of their life, with a particular focus on the subject of creativity. Three major themes emerged from the interviews: (1) Personal Growth, highlighting increased self-awareness, resilience in the face of adverse events and a deeper connection with their bodies; (2) Relationships with Others, underscoring shifts in friendships, family dynamics, and how relationships foster creativity; and (3) The Creative Self, which explores the redefinition of creativity in midlife as part of a broader transformative process. The study offers new insights into how midlife can serve as a fertile period for personal and creative development, challenging the dominant focus on loss often associated with ageing. This work contributes to the literature by highlighting the underexplored positive transformations occurring during this phase, particularly in the Italian socio-cultural context
Long-term experience with deferasirox (ICL670), a once-daily oral chelator, in the treatment of transfusional iron overload
No full textBackground: Chronic iron overload from frequent blood transfusions to treat patients with severe anaemias leads to significant morbidity and mortality. While deferoxamine, the current standard of care, is an effective iron chelator, it requires subcutaneous infusion for 8-12 h/ day, 5-7 days/week. This regimen is problematic and impacts significantly on patients' daily life. Objective: To evaluate the efficacy and tolerability of deferasirox, a once-daily oral iron chelator. Method: To review the available data reported in peer-reviewed journals (using PubMed) and at medical conferences. Results/conclusions: Deferasirox is effective in reducing or maintaining iron burden in patients with transfusion-dependent anaemias. As deferasirox is orally administered, the inconvenience of parenteral administration with deferasirox is avoided. Deferasirox improves patient satisfaction and is expected to improve compliance with iron chelation therapy
Unità mobili, attrezzate con apparecchiature a tecnologia avanzata di telecomunicazioni e telinformatica, atte a fornire prestazioni professionali e servizi specializzati in località minori disagiate
No full textUse of Non Contact Radar Techniques to Dynamics Measurement PurposesTopics in Modal Analysis II, Volume 6
No full textThe use of radar techniques to perform static (slowly moving) structural measurements is a well known task and most radar systems are limited to this kind of measurements. Recent progresses in this kind of techniques, however, have encouraged researchers to study and develop radar systems capable to perform dynamic measurements. The main advantage consists in the fact that this kind of system is a non-contact one. However, several problems may be encountered when using such a system to perform dynamic measurements. The aim of this work is to provide the validation of the prototype of a radar system (GBInSAR) developed by LiSALab, underlining the advantages and limitations in the use of this technique to perform dynamic measurements. The previous version of this system was usable to investigate phenomena with slow dynamics. The new system was tested imposing harmonic movements to a trihedron and measuring the displacements with the radar and with a set of accelerometers. Frequencies up to 20 Hz and displacements up to 10 + 10 mm were imposed during the tests. The tests were performed using one (shifting) reflecting body and nothing else in the scene and with the shifting reflecting body plus other three static reflecting bodies. A comparison between the results obtained with the two measurement techniques is proposed. © The Society for Experimental Mechanics, Inc. 2012
- …
